Veeda Clinical Research Limited IPO

The company derives a significant portion of its revenue from contracts with the company top clients. Its top five clients contributed more than 41.16% of the company revenue from contract with customers in the six months period ended September 30, 2024 with its top client that contributed approximately 28.37% of the company revenue from contract with customers in the six months period ended September 30, 2024. Loss of any of these clients could adversely affect its business, results of operations, cash flows and financial condition.

The potential loss or delay under any of its large contracts or of multiple key client contracts could adversely affect the company financial results specifically since the relationship of backlog to revenues varies over time and may not be fully realisable in the event of contract cancellation.

The company required to perform its services in accordance with contractual requirements, regulatory standards in applicable jurisdictions and ethical considerations. Any adverse action by any authority, including the Food and Drug Administration or the European Medicines Agency against it would negatively impact on the company ability to offer its services to the company clients and adversely impact its business and prospects.

If the company fails to deliver services in accordance with contractual requirements, the company could be subject to significant costs or liability and its reputation could be harmed.

The company has incurred losses for the six months period ended September 30, 2024 and Financial Year 2024 and may continue to do so in the future, which may adversely impact its business and the value of the Equity Shares.

The company financial performance is dependent on the company ability to secure business from clients in the pharmaceutical and biopharmaceutical industry. Consequently, any adverse changes in outsourcing trends in the pharmaceutical and biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect its operating results and growth rate.

The company studies and clinical trials could subject it to potential liability that may adversely affect its business, results of operations, cash flows and financial condition.

The company may not derives the anticipated benefits from its strategic investments and acquisitions, including the company acquisition of Heads and its may not be successful in pursuing future investments and acquisitions.

Failures to maintain confidential information of the company clients could adversely affect its business, results of operations, cash flows and financial condition and/or reputation.

The company is subject to risks arising from interest rate which could adversely affect its business, results of operations, cash flows and financial condition.